Atrium acquires Douglas Laboratories Canada


Atrium Biotechnologies Inc. announced the acquisition of the assets of London, Ontario based Douglas Laboratories Canada ("DL Canada"). DL Canada has been marketing Douglas Laboratories products in Canada since 2000 and has current annual revenues of approximately $5 million.

"This acquisition provides Atrium with a platform to develop the Canadian healthcare professional market not only for the Douglas Laboratories brand but also for the Pure Encapsulations brand which is not currently being sold in Canada. This acquisition further reinforces our current leadership position in North America and marks another step in our strategy to control access to markets and build solid organic growth for our brands," stated Richard Bordeleau, President of Atrium's Health & Nutrition Division.

In addition, Atrium will be able to benefit from the expertise and support of DL Canada's current management and staff who are staying on to ensure the successful integration and to sustain its growth.

Other news from the department business & finance

Most read news

More news from our other portals

Under the magnifying glass: The world of microscopy